Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

37.54 +0.60 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup
RPRX stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout above key resistance. 
Via Chartmill
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
Via MarketBeat
2 Reasons to Avoid RPRX and 1 Stock to Buy Instead
While the S&P 500 is up 23.9% since April 2025, Royalty Pharma (currently trading at $36.80 per share) has lagged behind, posting a return of 12.5%. This was partly due to its softer quarterly results... 
Via StockStory
Topics Government Stocks Supply Chain
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data
Via MarketBeat
3 Healthcare Stocks We Keep Off Our Radar
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the... 
Via StockStory
Topics Economy Stocks
How Do Investors Really Feel About Royalty Pharma?
 
Via Benzinga
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
Topics Economy
1 of Wall Street’s Favorite Stock to Keep an Eye On and 2 We Brush Off
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
A Look Into Royalty Pharma Inc's Price Over Earnings
 
Via Benzinga
How Is The Market Feeling About Royalty Pharma?
 
Via Benzinga
1 Value Stock with Exciting Potential and 2 We Avoid
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings
Royalty Pharma (RPRX) shows strong breakout potential with high technical and setup ratings, solid trend consistency, and clear support levels. Ideal for traders eyeing momentum stocks. 
Via Chartmill
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today
 
Via Benzinga
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.7% year on year to $578.7 million. Its non-GAAP profit of $1.14... 
Via StockStory
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Via The Motley Fool
Royalty Pharma PLC (NASDAQ:RPRX) Exceeds Q2 2025 Earnings Estimates and Raises Full-Year Guidance
Royalty Pharma (RPRX) beats Q2 2025 earnings with $727M revenue, up 20% YoY, driven by key therapies. Shares rise as company raises full-year guidance, reinforcing growth confidence. 
Via Chartmill
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per... 
Via StockStory
Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for. 
Via StockStory
Topics Government World Trade
2 Reasons to Watch RPRX and 1 to Stay Cautious
Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its... 
Via StockStory
Topics Stocks
3 Profitable Stocks to Research Further
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting... 
Via StockStory
Topics Supply Chain
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
2 Surging Stocks to Research Further and 1 to Be Wary Of
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch. 
Via Benzinga
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured... 
Via Stocktwits
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.